NCT06120283 2026-04-15
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
13 trialsNCT06638307 2026-04-13
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT06492616 2026-03-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05596409 2025-06-05
ELCIN
Stemline Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06938711 2025-04-22
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase 1/2 Withdrawn
NCT02338349 2022-08-18
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed
NCT02650817 2022-08-18
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed